Idera Pharmaceuticals CEO Vincent Milano's 2018 pay jumps 49% to $1.8M
Idera Pharmaceuticals reports 2018 executive compensation
By ExecPay News
Published: April 6, 2020
Idera Pharmaceuticals reported fiscal year 2018 executive compensation information on April 6, 2020.
In 2018, seven executives at Idera Pharmaceuticals received on average a compensation package of $1M, a 23% increase compared to previous year.
Average pay of disclosed executives at Idera Pharmaceuticals
Vincent J. Milano, Chief Executive Officer, received $1.8M in total, which increased by 49% compared to 2017. 56% of Milano's compensation, or $998K, was in option awards. Milano also received $150K in non-equity incentive plan, $600K in salary, as well as $34K in other compensation.
For fiscal year 2018, the median employee pay was $297,391 at Idera Pharmaceuticals. Therefore, the ratio of Vincent J. Milano's pay to the median employee pay was 6 to one.
Joanna Horobin, Chief Medical Officer, received a compensation package of $994K, which increased by 31% compared to previous year. 46% of the compensation package, or $462K, was in option awards.
Louis J. Arcudi, III, Chief Financial Officer, earned $986K in 2018, a 43% increase compared to previous year.
R. Clayton Fletcher, Senior Vice President, Business Development and Strategy, received $977K in 2018, which increases by 32% compared to 2017.
Jonathan Yingling, Chief Scientific Officer, earned $976K in 2018, a 11% decrease compared to previous year.
Bryant D. Lim, General Counsel, received $775K in 2018.
John J. Kirby, Vice President of Finance, Principal Financial and Accounting Officer, earned $554K in 2018, a 31% increase compared to previous year.
Related executives
Bryant Lim
Idera Pharmaceuticals
General Counsel
Vincent Milano
Idera Pharmaceuticals
Chief Executive Officer
R Fletcher
Idera Pharmaceuticals
Senior Vice President, Business Development and Strategy
Joanna Horobin
Idera Pharmaceuticals
Chief Medical Officer
John Kirby
Idera Pharmaceuticals
Chief Financial Officer
Jonathan Yingling
Idera Pharmaceuticals
Chief Scientific Officer
Louis Arcudi
Idera Pharmaceuticals
Chief Financial Officer
You may also like
Source: SEC filing on April 6, 2020.